secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nuvectis Pharma, Inc. (NVCT)
CIK:        0001875558
Form:       8-K
Filed at:   2025-02-06T23:59:59+00:00
Accession:  0001104659-25-009813
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nuvectis Pharma prices $13.5M public offering at $5/share; full over-allotment exercised
--------------------------------------------------------------------------------

- Priced 2.7M shares at $5.00 for $13.5M gross; underwriter fully exercised over-allotment of 405k shares, total gross $15.5M, net ~$14.4M.
- Net proceeds to fund development of NXP800 (Phase 1b ARID1a-mutated ovarian cancer) and NXP900 (Phase 1a SRC kinase inhibitor).
- Lucid Capital Markets sole book runner; offering closed February 6, 2025, after option exercise.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925009813/0001104659-25-009813-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1875558/000110465925009813/tm255441d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-009813

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer